Bayer
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. The brief covers the Pharmaceuticals division of Bayer AG only. Crop Science and Consumer Health are excluded, and a Leaps by Bayer investment counts only where the company's platform is AI or computational discovery for human medicines.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 6 | 4 | live, provisional | 3 | 5 |
| Research labs and data | 1 | claimed | claimed, provisional | 1 | 2 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
Bayer states an ambition to use AI to raise R&D productivity by 40 percent by 2030. AI in drug discovery scores 6 out of 10 for priority and 4 for delivery: the Tavros computer-based genomic screening platform is live at Vividion, Bayer's subsidiary, and Bayer chose Cradle after a successful proof of concept and contracted a three-year deployment for antibody work. Research labs and data scores 1 for priority, and delivery is shown as claimed, because Bayer says it is deploying digital technologies and data science in R&D but the sources show no identifiable system in operation. In the last 12 months Bayer made three AI commitments public, with Cradle, Vanderbilt University Medical Center and Iambic, against one in the year before, and expanded its TetraScience Scientific Data Foundry deployment in an announcement from the vendor that quotes Bayer. On 6 October 2026 it had 5 open R&D roles in AI in drug discovery and 2 in research labs and data, both of them Head of Machine Learning Research postings.
AI in drug discovery
Provisional: a published company document could not be read in full, so these scores may change.
What the company says: Priority 6
"Our ambition is to leverage AI to increase R&D productivity by 40 percent by 2030," said Sai Jasti, Senior Vice President, Head of Data Science & Artificial Intelligence, Bayer Pharmaceuticals R&D.
By integrating AI platform architecture with anonymized ... data, our data scientists are empowered to maximize our in-house biologics portfolio, validate AI models, and scale solutions, thereby ultimately speeding up drug discovery.
Through this acquisition, Bayer subsidiary Vividion Therapeutics Inc. is expanding its capabilities in terms of proprietary methods for computer-based genomic screening. ... Bayer paid an upfront consideration of around €19 million to acquire Tavros.
Bayer Annual Report 2025 (entire report PDF), 4 Mar 2026, p. 294
Combining the Tavros platform with Vividion’s chemoproteomics expertise and capabilities continues to greatly enhance Vividion’s efforts to generate potential best- and first-in-class drug targets across oncology and immunology.
Bayer Annual Report 2025 (entire report PDF), 4 Mar 2026, p. 47
Thanks to our strongest ever Pharma portfolio, our multimodal pipeline, and an increasingly AI-enabled operating model, we are on track to return to mid-single-digit growth from 2027 onwards
We continuously strive to improve our R&D productivity. Our key measures are centered around R&D excellence, an organizational set-up focused on our development products, dynamic resource allocation, data science and AI.
Bayer Annual Report 2025 (combined management report, sustainability statement), 4 Mar 2026, p. 34
Our strategic focus remains on delivering transformative medicines to patients faster, powered by our cutting-edge R&D expertise, dynamic operating model, partnership-driven innovation, AI-enabled development, and commitment to commercial excellence.
Not intended for U.S. and UK Media ... On the occasion of Bayer’s Pharma Media Day 2026
What it shows running: Delivery 4, live
Combining the Tavros platform with Vividion’s chemoproteomics expertise and capabilities continues to greatly enhance Vividion’s efforts to generate potential best- and first-in-class drug targets across oncology and immunology.
Bayer Annual Report 2025 (entire report PDF), 4 Mar 2026, p. 47
Following a successful proof of concept, Bayer selected Cradle as its best suited partner from among several vendors.
entered a three-year strategic collaboration to deploy Cradle's scientific AI software platform for protein engineering ... Bayer will integrate the generative AI platform into existing R&D workflows to enhance lead generation and optimization across its therapeutic antibody pipeline.
Under the agreement, Cradle will provide Bayer's antibody scientists with full access to its scientific AI software platform supporting a lab-in-the-loop approach
Cradle ... Strategic collaboration to strengthen AI-powered research and optimization of antibodies
Bayer Annual Report 2025 (combined management report, sustainability statement), 4 Mar 2026, p. 54
today announced a drug discovery collaboration in which Bayer will discover new medicines using Iambic's AI-driven platform. The collaboration is focused on small molecule discovery.
Under terms of the agreement Iambic will receive an upfront payment as well as milestone and royalty payments.
In June, we entered into a research collaboration with the biopharmaceutical tech company Iambic Therapeutics Inc. to accelerate drug discovery using artificial intelligence (AI).
By integrating AI platform architecture with anonymized ... data, our data scientists are empowered to maximize our in-house biologics portfolio, validate AI models, and scale solutions, thereby ultimately speeding up drug discovery.
Bayer's strategic partnerships with organizations Vanderbilt University Medical Center in the U.S., FinnGen in Finland, and PRECISE in Singapore, leverage a global ecosystem that combines anonymized data and AI-driven analytics, expediting drug discovery
Commitments made public in the last 12 months: 3
- Iambic AI small-molecule discovery collaboration: Small-molecule discovery collaboration giving Bayer use of Iambic AI platform including Enchant and NeuralPLexer models. New, announced, 22 Jun 2026. Published by: joint release.
- Vanderbilt University Medical Center discovery collaboration (BioVU data): Five-year discovery collaboration using VUMC BioVU data resources from target identification to IND; AI link stated later. New, announced, 20 Jan 2026. Published by: joint release.
- Cradle AI protein engineering platform collaboration (antibodies): Three-year deal to deploy Cradle generative AI protein engineering platform in Bayer antibody discovery workflows. New, announced, 7 Jan 2026. Published by: joint release.
Commitments made public in the year before: 1
- Vividion acquisition of Tavros Therapeutics (functional and computational genomics): Bayer subsidiary Vividion acquired Tavros, adding its functional and computational genomics target discovery platform. New, operational, 8 Jan 2025. Published by: company.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 5
- Head of Machine Learning Research, Whippany,New Jersey,United States
- Head of Machine Learning Research (all genders), Berlin,Berlin,Germany
- Senior Principal Scientist (all genders) - Quantum Mechanics and Modeling, Wuppertal-Aprath,North Rhine Westfalia,Germany
- Principal Machine Learning Scientist (all genders), Berlin,Berlin,Germany
- Principal Machine Learning Scientist (all genders), Wuppertal-Aprath,North Rhine Westfalia,Germany
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Research labs and data
Provisional: a published company document could not be read in full, so these scores may change.
What the company says: Priority 1
focus on the systematic implementation of digital technologies and the deployment of data sciences to increase the speed, reliability and effectiveness of our R&D processes.
Bayer Annual Report 2025 (combined management report, sustainability statement), 4 Mar 2026, p. 45
What it shows running: Delivery claimed, claimed
focus on the systematic implementation of digital technologies and the deployment of data sciences to increase the speed, reliability and effectiveness of our R&D processes.
Bayer Annual Report 2025 (combined management report, sustainability statement), 4 Mar 2026, p. 45
Commitments made public in the last 12 months: 1
- TetraScience Scientific Data Foundry deployment: Bayer to expand TetraScience Scientific Data Foundry across pharmaceutical and crop science R&D operations. Expanded, announced, 20 Nov 2025. Published by: partner release, company quoted.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 2
- Head of Machine Learning Research, Whippany,New Jersey,United States
- Head of Machine Learning Research (all genders), Berlin,Berlin,Germany
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Two questions to investigate (Ortent's interpretation)
- TetraScience says Bayer uses its Scientific Data Foundry for instrument and contract research data across pharmaceutical and crop science R&D, run by digital and IT teams, while the new Head of Machine Learning Research is to build a separate discovery data foundation. Who decides on additions to the scientific data stack, and how do the two connect?
- Bayer's AI discovery deals are announced by different executives: drug discovery sciences for Cradle, and business development and licensing for Iambic, Vanderbilt and Tavros. Who holds the decision to license an outside AI discovery platform, does a selection like Cradle's go through procurement, and how is funding set against the 40 percent productivity ambition?
Coverage limits
Both themes are provisional because a published company document, Bayer's Q2 2026 call transcript and presentation, could not be read in full. bayer.com blocked access outside its newsroom, so investor slides, call transcripts and the Bayer Pharma AI page were not read, and the Annual Report 2024 was read only in part; the Annual Report 2025 was read in full. Business Wire, GlobeNewswire, Leaps by Bayer, Fierce Biotech and parts of PR Newswire were out of reach, and searches for Bayer lab notebook, LIMS and data platform news were not run, so research labs and data evidence may be incomplete.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call